Using machine learning to predict heart events in patients with hypertrophic cardiomyopathy
Phénogroupage basé Sur l'Apprentissage Automatique Dans la Cardiomyopathie Hypertrophique Pour Identifier Les Facteurs prédictifs de la Fibrose Myocardique et Les événements Cardiovasculaires
This study is testing a new computer program that uses heart imaging data to see if it can help predict heart problems in people with hypertrophic cardiomyopathy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 870 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Central Hospital, Nancy, France Academic / other |
| Locations | 2 sites (Bordeaux and 1 other locations) |
| Trial ID | NCT06256913 on ClinicalTrials.gov |
What this trial studies
This study aims to develop and validate a machine learning algorithm that utilizes echocardiographic data to predict cardiovascular events in patients diagnosed with sarcomeric hypertrophic cardiomyopathy. By analyzing cardiac imaging data, the researchers hope to identify risk factors and improve patient outcomes. The approach involves supervised learning techniques to create a predictive model tailored to the unique characteristics of this condition. The study is observational, focusing on real-world data without any specified interventions.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with a confirmed diagnosis of sarcomeric hypertrophic cardiomyopathy.
Not a fit: Patients with echocardiographic data that cannot be adequately analyzed or those with other conditions causing left ventricular hypertrophy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly enhance the ability to predict serious cardiovascular events in patients with hypertrophic cardiomyopathy, leading to better management and outcomes.
How similar studies have performed: While machine learning approaches in cardiovascular prediction are gaining traction, this specific application in hypertrophic cardiomyopathy is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \>18 * Patients with confirmed sarcomeric hypertrophic cardiomyopathy Exclusion Criteria: * Echocardiographic data not allowing deep analysis (technical default, bad echogenicity of the patient) * Other causes of left ventricular hypertrophy that may hamper the diagnosis (p.e. aortic or sub-aortic stenosis, severe renal insufficiency, hypertension). * History of ischemic heart disease or associated myocarditis * Opposition of the patient to the use of his/her data
Where this trial is running
Bordeaux and 1 other locations
- CHU de Boredeaux Hôpital Cardiologique du Haut-Lévêque — Bordeaux, France (Recruiting)
- CHRU de Nancy — Nancy, France (Recruiting)
Study contacts
- Study coordinator: Olivier Huttin, MD, PhD
- Email: o.huttin@chru-nancy.fr
- Phone: + 33 3 83 15 73 55
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.